Welcome to our dedicated page for Agenus news (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus stock.
Agenus Inc (AGEN) is a clinical-stage biotechnology company pioneering novel immunotherapies to combat cancer and infectious diseases. This page provides centralized access to official press releases, financial updates, and scientific developments from Agenus, offering stakeholders a reliable resource for tracking the company’s progress.
Investors and researchers will find timely updates on clinical trial milestones, regulatory filings, and strategic partnerships, alongside analyses of AGEN’s proprietary platforms like Retrocyte Display™ antibody technology. The curated news collection enables efficient monitoring of the company’s immuno-oncology pipeline and manufacturing advancements through its integrated cGMP facilities.
Key categories include earnings reports, therapy development updates, licensing agreements, and peer-reviewed research highlights. Bookmark this page to stay informed about AGEN’s innovations in checkpoint modulators, cell therapies, and vaccine adjuvants without navigating multiple sources.
Agenus (Nasdaq: AGEN) reported updated clinical data for the botensilimab (BOT) plus balstilimab (BAL) combination from expansion cohorts of the Phase 1b C-800-01 study presented at ESMO 2025. Across 411 enrolled patients (339 evaluable), the pan-tumor dataset showed a 2-year overall survival (OS) of 39%, median OS of 17.2 months, and objective response rate (ORR) of 17%. Sixty-one percent received ≥3 prior lines of therapy. The combo was generally tolerable with reversible immune-related GI events and no treatment-related deaths. France granted compassionate access for BOT+BAL in refractory MSS mCRC.
Agenus (Nasdaq: AGEN) will host a virtual Stakeholder Briefing on Tuesday, October 21, 2025 at 4:00 p.m. ET to share post-ESMO clinical updates and global access progress for its immunotherapy combination botensilimab (BOT) and balstilimab (BAL).
Speakers include Michael S. Gordon, MD, discussing ESMO 2025 results from >400 patients treated with BOT/BAL across refractory solid tumors, and Alexander M.M. Eggermont, MD, PhD, on France’s AAC program and BOT/BAL inclusion. The session, moderated by Garo Armen, will end with live Q&A. No pre-registration is required and a webcast link is provided.
Agenus (NASDAQ: AGEN) has achieved a significant milestone as its investigational combination therapy botensilimab plus balstilimab (BOT/BAL) receives reimbursed compassionate access in France for treating refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
The treatment will be available through France's Accès compassionnel (AAC) framework, with 100% coverage by Assurance Maladie for eligible patients. Clinical data shows promising results, including ~21-month median overall survival, ~42% 2-year survival, and ~20% objective response rate in expanded cohorts.
The AAC authorization enables hospital use with full reimbursement at the invoiced purchase price, outside the Diagnosis-related Group. EU/EEA patients may access the treatment in France under specific directives, while non-EU countries like Turkey can participate through treatment-abroad programs.
Agenus (NASDAQ:AGEN), an immuno-oncology company, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City.
The company's executives, Dr. Richard Goldberg (Chief Development Officer) and Dr. Robin Taylor (Chief Commercial Officer), will conduct a fireside chat on September 9, 2025, from 10:00-10:30 AM EST. They will discuss the BOT/BAL immunotherapy program, including updates on the pivotal Phase 3 BATTMAN trial in metastatic colorectal cancer, clinical data, partnerships, and upcoming milestones for H2 2025.
Agenus (Nasdaq: AGEN), a leader in immuno-oncology, has announced updated details for its virtual Stakeholder Briefing scheduled for August 27, 2025, at 4:00 p.m. ET. The webcast will feature a new virtual format and updated participation link, requiring no pre-registration.
The briefing will cover several key areas including strategic and financial overview, Zydus partnership updates, colorectal cancer (CRC) studies, BOT/BAL clinical updates, and Phase 3 BATTMAN study in metastatic CRC. Additionally, the session will spotlight MiNK Therapeutics, where Agenus holds a significant stake.
Distinguished speakers include CEO Garo H. Armen, Chief Development Officer Richard M. Goldberg, and other experts in GI oncology and cancer research. The event will conclude with a live Q&A session.
Agenus (NASDAQ: AGEN), an immuno-oncology company, will host a virtual Stakeholder Briefing on August 27, 2025, at 4:00 p.m. ET. The event will feature presentations from senior management and industry experts focusing on developments in cancer treatment.
Key topics include strategic updates on the botensilimab (BOT) and balstilimab (BAL) programs, progress following the Zydus partnership, colorectal cancer (CRC) studies including the Phase 3 BATTMAN study, and future milestones. Notable speakers include CEO Garo H. Armen, MiNK Therapeutics CEO Jennifer Buell, and newly appointed Chief Development Officer Richard M. Goldberg, along with experts from Duke University and the Canadian Cancer Trials Group.
Agenus (NASDAQ:AGEN) reported Q2 2025 financial results and significant progress in its immunotherapy program. The company's BOT/BAL combination therapy demonstrated a remarkable 42% two-year survival rate in refractory MSS colorectal cancer patients. The FDA has agreed to a streamlined two-arm Phase 3 BATTMAN trial design, set to begin in Q4 2025.
Financial highlights include Q2 2025 revenue of $25.7M and reduced net loss of $56.4M YTD. A strategic collaboration with Zydus Lifesciences is expected to close in Q3 2025, bringing $91M in capital infusion. The company also partnered with Noetik AI for biomarker development and maintains significant ownership in MiNK Therapeutics and SaponiQx.
Agenus (NASDAQ: AGEN), an immuno-oncology company, has scheduled two important upcoming events. The company will first release its Q2 2025 financial results before market opens on August 11, 2025. Following this, Agenus will host a stakeholder briefing in late August to discuss strategic plans, data milestones, and provide updates on their botensilimab (BOT) and balstilimab (BAL) development program.
Agenus (NASDAQ:AGEN) announced the acceptance of four abstracts for presentation at the ESMO Congress 2025 in Berlin, showcasing progress in their immunotherapy programs. The highlight is an oral presentation featuring emerging survival plateaus from a study of botensilimab plus balstilimab combination in 343 evaluable patients with refractory metastatic solid tumors across five tumor types.
Three additional poster presentations will showcase data from investigator-sponsored studies in cervical cancer, MSS metastatic colorectal cancer (mCRC), and non-melanoma skin cancers. These presentations demonstrate the broad potential of botensilimab and balstilimab combinations in treating difficult-to-treat cancers. The presentations will take place between October 17-21, 2025.
GSK (NYSE:GSK) has received FDA approval for a new prefilled syringe presentation of SHINGRIX, its vaccine for preventing shingles. This new format eliminates the need to reconstitute separate vials before administration, streamlining the vaccination process for healthcare professionals.
The approval is based on data showing technical comparability between the new and existing presentations. SHINGRIX remains indicated for adults aged 50 years and older, and those 18 years and older with increased shingles risk due to immunodeficiency. The CDC continues to recommend two doses of the vaccine for these populations.
The prefilled syringe presentation is currently under review by the European Medicines Agency, with filing acceptance received in January 2025.
FAQ
What is the current stock price of Agenus (AGEN)?
What is the market cap of Agenus (AGEN)?
